Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Tuesday 09 July, 2019

Oxford BioDynamics

Director/PDMR Shareholding

RNS Number : 9093E
Oxford BioDynamics PLC
09 July 2019
 

9 July 2019

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing

 

Oxford BioDynamics Plc (AIM: OBD) announces that today it received notification that Christian Hoyer Millar, Chief Executive Officer, Paul Stockdale, Chief Financial Officer, and Vulpes Life Sciences Fund, which is controlled by Non-Executive Chairman Stephen Diggle, have each purchased Ordinary Shares of 1 pence each as follows:

 

Name

Number of shares purchased

Average price per share

Christian Hoyer Millar

14,000

£1.2525

Paul Stockdale

7,814

£1.2786

Vulpes Life Sciences Fund

10,000

£1.2500

 

Following this transaction, Christian Hoyer Millar, together with his wife, is interested in 12,340,303 Ordinary Shares, representing approximately 13.33% of the Company's current issued share capital, Paul Stockdale is interested in 7,814 Ordinary Shares, representing approximately 0.01% of the Company's current issued share capital, and Vulpes Life Sciences Fund is interested in 11,633,183 Ordinary Shares, representing approximately 12.57% of the Company's current issued share capital.

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stephen Diggle

2

Reason for the notification

a)

Position/status 

Director/PDMR

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each

 

ISIN:   GB00BD5H8572

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.2500

10,000

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

Price

Volume

£1.2500

10,000

 

 

e)

Dates of the transactions

8 July 2019

 

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christian Hoyer Millar

2

Reason for the notification

a)

Position/status 

Director/PDMR

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each

 

ISIN:   GB00BD5H8572

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.2296

5,000

£1.2500

3,000

£1.2609

2,000

£1.2694

2,000

£1.2885

2,000

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

Price

Volume

£1.2525

14,000

 

 

e)

Dates of the transactions

5 and 8 July 2019

 

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Paul Stockdale

2

Reason for the notification

a)

Position/status 

Director/PDMR

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each

 

ISIN:   GB00BD5H8572

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.2600

1,984

£1.2850

5,830

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

Price

Volume

£1.2786

7,814

 

 

e)

Date of the transaction

5 July 2019

 

f)

Place of the transaction

Outside a trading venue

 

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital

Nominated Adviser and Broker

Stephane Auton

Edward Mansfield

+44 (0)20 7408 4090

FTI Consulting

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHLIFSEDVIAIIA

a d v e r t i s e m e n t